Jin-hong Chang

Dr. Jin-hong Chang

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Survey of Ophthalmology
Verified
Journal Article
Closed access
JCJin-hong Chang
Jin-hong Chang
NGNitin K. Garg
Nitin K. Garg
ELElisa Lunde
Elisa Lunde
KHKyu-Yeon Han
Kyu-Yeon Han
SJSandeep Jain
Sandeep Jain
DADimitri T Azar
Dimitri T Azar

1 May 2010 in Progress in Retinal and Eye Research
Verified
Journal Article
Closed access
DEDavid Ellenberg
David Ellenberg
DADimitri T Azar
Dimitri T Azar
JHJoelle A. Hallak
Joelle A. Hallak
FTFaisal Tobaigy
Faisal Tobaigy
KHKyu Yeon Han
Kyu Yeon Han
JCJin-hong Chang
Jin-hong Chang

1 December 2015 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
AWAmit Walia
Amit Walia
JYJessica F. Yang
Jessica F. Yang
YHYu-Hui Huang
Yu-Hui Huang
MRMark I. Rosenblatt
Mark I. Rosenblatt
JCJin-hong Chang
Jin-hong Chang
DADimitri T. Azar
Dimitri T. Azar

1 July 2018 in Survey of Ophthalmology
Verified
Journal Article
Closed access
WZWei Zhong
Wei Zhong
MMMario Montana
Mario Montana
SSSamuel M. Santosa
Samuel M. Santosa
IIIrene D. Isjwara
Irene D. Isjwara
YHYu-Hui Huang
Yu-Hui Huang
DADimitri T Azar
Dimitri T Azar

12 March 2018 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
MYMichael Yamakawa
Michael Yamakawa
SDSusan J. Doh
Susan J. Doh
SSSamuel M. Santosa
Samuel M. Santosa
MMMario Montana
Mario Montana
EQEllen C. Qin
Ellen C. Qin
DADimitri T. Azar
Dimitri T. Azar

1 March 2013 in Journal of Ocular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
LGLilian Gonzalez
Lilian Gonzalez
RLRaymond J. Loza
Raymond J. Loza
KHKyu-Yeon Han
Kyu-Yeon Han
SSSuhair Sunoqrot
Suhair Sunoqrot
CCChristy Cunningham
Christy Cunningham
JCJin-hong Chang
Jin-hong Chang
Nanotechnology is an up-and-coming branch of science that studies and designs materials with at least one dimension sized from 1–100 nm. These nanomaterials have unique functions at the cellular, atomic, and molecular levels.1 The term “nanotechnology” was first coined in 1974.2 Since then, it has evolved dramatically and now consists of distinct and independent scientific fields. Nanotechnology is a highly studied topic of interest, as nanoparticles can be applied to various fields ranging from medicine and pharmacology, to chemistry and agriculture, to environmental science and consumer goods.3 The rapidly evolving field of nanomedicine incorporates nanotechnology with medical applications, seeking to give rise to new diagnostic means, treatments, and tools. Over the past two decades, numerous studies that underscore the successful fusion of nanotechnology with novel medical applications have emerged. This has given rise to promising new therapies for a variety of diseases, especially cancer. It is becoming abundantly clear that nanotechnology has found a place in the medical field by providing new and more efficient ways to deliver treatment. Ophthalmology can also stand to benefit significantly from the advances in nanotechnology research. As it relates to the eye, research in the nanomedicine field has been particularly focused on developing various treatments to prevent and/or reduce corneal neovascularization among other ophthalmologic disorders. This review article aims to provide an overview of corneal neovascularization, currently available treatments, and where nanotechnology comes into play.